Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

NCT04331067 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04331067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04331067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Terminated
Start date
November 19, 2020
Completion date
June 9, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer